Zobrazeno 1 - 10
of 805
pro vyhledávání: '"Witkiewicz, Agnieszka"'
Autor:
Witkiewicz, Agnieszka K., Chung, Sejin, Brough, Rachel, Vail, Paris, Franco, Jorge, Lord, Christopher J., Knudsen, Erik S.
Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically antagonized by the retinoblastom
Externí odkaz:
http://hdl.handle.net/10150/627049
http://arizona.openrepository.com/arizona/handle/10150/627049
http://arizona.openrepository.com/arizona/handle/10150/627049
Recently developed potent and selective CDK4/6 inhibitors fall into two classes based on structure and toxicity profiles in clinical studies. One class, exemplified by palbociclib and ribociclib, exhibits neutropenia as a dose-limiting toxicity and r
Externí odkaz:
http://hdl.handle.net/10150/625360
http://arizona.openrepository.com/arizona/handle/10150/625360
http://arizona.openrepository.com/arizona/handle/10150/625360
Autor:
Witkiewicz, Agnieszka K, Balaji, Uthra, Eslinger, Cody, McMillan, Elizabeth, Conway, William, Posner, Bruce, Mills, Gordon B, O'Reilly, Eileen M, Knudsen, Erik S
Pancreatic ductal adenocarcinoma (PDAC) harbors the worst prognosis of any common solid tumor, and multiple failed clinical trials indicate therapeutic recalcitrance. Here, we use exome sequencing of patient tumors and find multiple conserved genetic
Externí odkaz:
http://hdl.handle.net/10150/621251
http://arizona.openrepository.com/arizona/handle/10150/621251
http://arizona.openrepository.com/arizona/handle/10150/621251
Autor:
Knudsen, Erik S., Balaji, Uthra, Freinkman, Elizaveta, McCue, Peter, Witkiewicz, Agnieszka K.
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The aggressiveness and therapeutic recalcitrance of this malignancy has been attributed to multiple factors including the influence of an active desmoplastic stroma. How the stromal micr
Externí odkaz:
http://hdl.handle.net/10150/622479
http://arizona.openrepository.com/arizona/handle/10150/622479
http://arizona.openrepository.com/arizona/handle/10150/622479
ER positive (ER+) and HER2 negative (HER2-) breast cancers are routinely treated based on estrogen dependence. CDK4/6 inhibitors in combination with endocrine therapy have significantly improved the progression-free survival of patients with ER+/HER2
Externí odkaz:
http://hdl.handle.net/10150/622114
http://arizona.openrepository.com/arizona/handle/10150/622114
http://arizona.openrepository.com/arizona/handle/10150/622114
Publikováno v:
In Trends in Cell Biology August 2024 34(8):636-645
Autor:
Szarszoń, Klaudia, Mikołajczyk, Aleksandra, Grelich-Mucha, Manuela, Wieczorek, Robert, Matera-Witkiewicz, Agnieszka, Olesiak-Bańska, Joanna, Rowińska-Żyrek, Magdalena, Wątły, Joanna
Publikováno v:
In Journal of Inorganic Biochemistry April 2024 253
Autor:
Mohammadpour, Hemn, Tsuji, Takemasa, MacDonald, Cameron R., Sarow, Joseph L., Rosenheck, Hanna, Daneshmandi, Saeed, Choi, Jee Eun, Qiu, Jingxin, Matsuzaki, Junko, Witkiewicz, Agnieszka K., Attwood, Kristopher, Blazar, Bruce R., Odunsi, Kunle, Repasky, Elizabeth A., McCarthy, Philip L.
Publikováno v:
In Cell Reports 28 March 2023 42(3)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.